Pramodini Medicare IPO: GMP, Pricing, Allotment Details, and Profit Predictions for 2026 Unveiled!

Pramodini Medicare is set to launch its IPO from August 12 to August 14, 2026, with an issue price range of INR 110 to 118 per share. The IPO consists of a fresh issue of 5,350,800 shares, aiming to raise approximately INR 58.86 to 63.14 crore, along with an offer for sale of 500,400 shares expected to generate an additional INR 5.50 to 5.90 crore. The total size of the IPO is estimated to be between INR 64.36 and 69.04 crore, making it a significant entry into the Indian diagnostics market. The company operates 16 diagnostic centers across seven states, bolstered by a strong tech-enabled service portfolio focusing on radiology and clinical laboratory services.

In terms of market sentiment, the current grey market premium (GMP) for the Pramodini Medicare IPO remains to be determined. However, early indicators suggest a cautiously optimistic outlook from investors, as the company’s financial performance shows promising growth —with revenue increasing from INR 35.23 crore in FY2024 to INR 62.29 crore in FY2026. Investors are likely to evaluate the company’s significant revenue contributions from its core radiology services, which accounted for over 97% of operating revenue in FY26, reflecting both demand and operational efficiency, which could positively influence its market position upon listing.

For Indian investors, the Pramodini Medicare IPO presents a strategic opportunity to enter a growing sector in healthcare diagnostics, particularly in radiology and associated services. With the backing of partnerships with various hospitals and a steady increase in diagnostic tests provided, the company’s robust growth trajectory may translate into favorable long-term returns. Investors should also monitor the overall market conditions and investor sentiment as the IPO date approaches to make informed investment decisions.

Source: The Economic Times

(Expert Note: This report was prepared by the Wealthova IPO team.)